teplizumab

Home
Ligands
teplizumab

GtoPdb Ligand ID: 12252

Synonyms: humanized OKT3 | MGA031 | PRV-031 | teplizumab-mzwv | Tzield®

teplizumab is an approved drug (FDA (2022))

Comment: Teplizumab is a humanized anti-CD3e monoclonal antibody that was originally developed as an immunomodulatory agent. Structurally it is a modified version of the mouse antibody muromonab-CD3 (mOKT3) that has been used to reverse steroid-resistant renal allograft rejection. Alterations in the OKT3 CH2 domain disrupt Fcγ receptor binding, and blocks antibody-mediated effector cells functions and cytokine release [5,7]. It was advanced to extended clinical evaluations for potential to protect pancreatic β-cells in newly diagnosed type 1 diabetes (T1D) patients [4,6], following evidence that it impaired expansion of alloreactive anti-β cell T cells [5], and that a single short course of teplizumab treatment could induce a long-lasting improvement in patients' C-peptide responses and clinical parameters (including preservation of insulin production) in the early stages of T1D [2-3].

Immunopharmacology Comments
Like other anti-CD3e agents, teplizumab has immunosuppressive activity. It was engineered to minimise the human anti-mouse antibody and "cytokine release syndrome" responses that are associated with its parent antibody muromonab-CD3.

Immunopharmacology Comments

Like other anti-CD3e agents, teplizumab has immunosuppressive activity. It was engineered to minimise the human anti-mouse antibody and "cytokine release syndrome" responses that are associated with its parent antibody muromonab-CD3.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Diabetes mellitus, insulin-dependent; IDDM	Disease Ontology: DOID:9744 OMIM: 222100	Approved drug: Delays immune-mediated damage of pancreatic β cells and preserves insulin production in the early stages of T1DM.